{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:20Z","timestamp":1787027060558,"version":"build-2736575974"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aimed to assess the characteristics of adverse drug reactions (ADRs) collected in a university hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis of ADRs spontaneously reported in the Hospital Pharmacovigilance Program database (RutiRAM) over a 13-year period was conducted. The analysis included a description of ADRs [System Organ Class (SOC)] and their seriousness, the drugs involved [level 1 of the Anatomical Therapeutic Chemical (ATC) Classification System], drug-drug interactions, medication errors, drugs \u2018under additional monitoring\u2019, positive rechallenge, and the \u2018pharmacovigilance interest\u2019 of ADRs. An ADR was considered of \u2018pharmacovigilance interest\u2019 when it was serious, and\/or produced sequelae, and\/or affected the paediatric population, and\/or when the suspected drug was \u2018under additional monitoring\u2019. Additionally, an exploratory analysis for bivariate associations through an automated method was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2,148 spontaneous ADRs were registered in the RutiRAM database, with 92.5% recorded by medical doctors. The mean age of cases was 59.2\u00a0years (SD 20.9), range 1 day\u201399\u00a0years; 5.7% were paediatric, 46.2% adults, and 48.1% elderly. The drugs most often involved were anti-infectives (ATC group J), mainly amoxicillin-clavulanic acid. \u2018Blood system disorders\u2019 were the most frequent SOC ADRs, and skin rashes were the most frequent ADRs. The 63.2% of ADRs were considered of \u2018pharmacovigilance interest\u2019. Almost half of ADRs were hospital-acquired, and these were related to medication error; serious ADRs were related to drug-drug interactions and elderly patients, and involved drugs \u2018under additional monitoring\u2019 were related to younger ones.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first study to overview of ADRs reported in an HPVP over more than a decade. Almost two-thirds of the ADRs collected in the RutiRAM database are of sufficient quality to be classified as \u2018pharmacovigilance interest\u2019, and thus can contribute to signal detection and the issuing of drug alerts by pharmacovigilance systems. Analysing ADRs in hospitals contributes to patient safety by implementing relevant actions to prevent medication errors or ADRs, some of which can be applied to other centres.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1427772","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T23:26:06Z","timestamp":1733354766000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Spontaneous adverse drug reactions reported in a thirteen-year pharmacovigilance program in a tertiary university hospital"],"prefix":"10.3389","volume":"15","author":[{"given":"E.","family":"Montan\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"P\u00e9rez-Ma\u00f1\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Papaseit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hladun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"De la Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Farr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/BF03262002","article-title":"Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase\u2122","volume":"35","author":"Aagaard","year":"2012","journal-title":"Drug Saf."},{"key":"B2","unstructured":"National coordinating council for medication error reporting and prevention2024"},{"key":"B3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/jcpt.13306","article-title":"Adverse drug reactions spontaneously reported at a tertiary care hospital and preventable measures implemented","volume":"46","author":"Abu Esba","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.medcli.2016.06.012","article-title":"Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system","volume":"147","author":"Aguirre","year":"2016","journal-title":"Med. Clin. Barc."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s11096-015-0185-1","article-title":"Adverse drug reactions experience in a teaching hospital in Jordan","volume":"37","author":"Alsbou","year":"2015","journal-title":"Int. J. Clin. Pharm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.3390\/jcm10184053","article-title":"Drug-related deaths in a tertiary hospital: characteristics of spontaneously reported cases and comparison to cases detected from a retrospective study","volume":"10","author":"Arellano","year":"2021","journal-title":"J. Clin. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1365-2125.1994.tb04373.x","article-title":"False-positives in spontaneous reporting: should we worry about them?","volume":"38","author":"Begaud","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B8","first-page":"84","article-title":"Farmacovigilancia hospitalaria en Buenos Aires [Hospital pharmacovigilance in Buenos Aires]","volume":"74","author":"Brodsky","year":"2014","journal-title":"Med. (B Aires)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3238\/arztebl.2012.0546","article-title":"Drug interactions--principles, examples and clinical consequences","volume":"109","author":"Cascorbi","year":"2012","journal-title":"Dtsch. Arztebl Int."},{"key":"B10","article-title":"Commission directive 2010\/84\/EU of the European Parliament and the council of 15 December 2010 amending as regards pharmacovigilance, directive 2001\/83\/EC on the community code relating to medicinal products for human use","volume":"31","year":"2010","journal-title":"Official J. Eur. Union"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e4439","DOI":"10.1371\/journal.pone.0004439","article-title":"Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes","volume":"4","author":"Davies","year":"2009","journal-title":"PLoS One"},{"key":"B12","unstructured":"EMA recommends measures to minimise serious outcomes of known side effect with painkiller metamizole2024"},{"key":"B14","unstructured":"Memo\/08\/782. Strengthening pharmacovigilance to reduce adverse effects of medicines2024"},{"key":"B15","article-title":"ICH topic E2D","volume-title":"Post approval safety data management","year":"2004"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1211786","DOI":"10.3389\/fphar.2023.1211786","article-title":"Unknown adverse drug reactions from spontaneous reports in a hospital setting: characterization, follow-up, and contribution to the pharmacovigilance system","volume":"14","author":"Filippi-Arriaga","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.vascn.2016.04.011","article-title":"Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital","volume":"81","author":"Geer","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods."},{"key":"B19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2125.1987.tb03011.x","article-title":"Conclusiveness of rechallenge in the interpretation of adverse drug reactions","volume":"23","author":"Girard","year":"1987","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B20","volume":"3","year":"2017","journal-title":"Module VIII \u2013 Post-authorisation Saf. Stud. EMA\/813938\/2011 Rev."},{"key":"B21","unstructured":"Individual case safety reports for healthcare professionals2014"},{"key":"B22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"B24","first-page":"7","article-title":"Starting a pharmacovigilance program within a teaching hospital: challenges and experiences from Lalitpur, Nepal","volume":"2","author":"Jha","year":"2009","journal-title":"South Med. Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2174\/1574886315666200731172405","article-title":"Spontaneous adverse drug reaction monitoring in a tertiary care centre","volume":"15","author":"Kaur","year":"2020","journal-title":"Curr. Drug Saf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/bab.1617","article-title":"Progress in biopharmaceutical development","volume":"65","author":"Kesik-Brodacka","year":"2018","journal-title":"Biotechnol. Appl. Biochem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/14740338.2017.1316486","article-title":"Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation","volume":"16","author":"Leporini","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"624562","DOI":"10.3389\/fphar.2020.624562","article-title":"Spontaneous reports of serious adverse drug reactions resulting from drug-drug interactions: an analysis from the French pharmacovigilance database","volume":"11","author":"L\u00e9tinier","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B29","year":"2024"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2050-6511-14-5","article-title":"Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil","volume":"14","author":"Lobo","year":"2013","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.3390\/jcm10235531","article-title":"Spontaneous reporting of adverse drug reactions in a pediatric population in a tertiary hospital","volume":"10","author":"L\u00f3pez-Valverde","year":"2021","journal-title":"J. Clin. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ejim.2014.10.001","article-title":"Understanding adverse drug reactions in older adults through drug-drug interactions","volume":"25","author":"Marengoni","year":"2014","journal-title":"Eur. J. Intern Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/ijpp.12078","article-title":"A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal","volume":"22","author":"Marques","year":"2014","journal-title":"Int. J. Pharm. Pract."},{"key":"B34","unstructured":"Introductory guide MedDRA version 26.02023"},{"key":"B35","year":"2024"},{"key":"B36","first-page":"191","article-title":"An\u00e1lisis de las notificacions recibidas en la unidad de farmacovigilancia de la Sociedad Espa\u00f1ola de farm\u00e0cia Hospitlaria 1990-1998","volume":"23","author":"Molina-Castiella","year":"1999","journal-title":"Farm Hosp."},{"key":"B37","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/bcp.13471","article-title":"Drug-related deaths in hospital inpatients: a retrospective cohort study","volume":"84","author":"Montan\u00e9","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1111\/bcp.14799","article-title":"Epidemiology of drug-related deaths in European hospitals: a systematic review and meta-analysis of observational studies","volume":"87","author":"Montan\u00e9","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.medcli.2019.08.007","article-title":"Adverse drug reactions","volume":"154","author":"Montan\u00e9","year":"2020","journal-title":"Med. Clin. Barc."},{"key":"B40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/14740338.2020.1849137","article-title":"Adverse drug reactions in elderly: a five-year review of spontaneous reports to the Portuguese pharmacovigilance system","volume":"20","author":"Monteiro","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"B41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/0897190011431146","article-title":"Anticoagulants: therapeutics, risks, and toxicity--special emphasis on heparin-induced thrombocytopenia (HIT)","volume":"25","author":"O'Donnell","year":"2012","journal-title":"J. Pharm. Pract."},{"key":"B42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40264-012-0014-6","article-title":"WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems","volume":"36","author":"Pal","year":"2013","journal-title":"Drug Saf."},{"key":"B43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.7399\/fh.11169","article-title":"Integrating pharmacovigilance into the routine of pharmacy department: experience of nine years","volume":"43","author":"P\u00e9rez-Ricart","year":"2019","journal-title":"Farm Hosp."},{"key":"B44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ"},{"key":"B45","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/096032718300200401","article-title":"Deliberate drug rechallenge","volume":"2","author":"Stephens","year":"1983","journal-title":"Hum. Toxicol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.4103\/0976-500X.120957","article-title":"Clinical and economic burden of adverse drug reactions","volume":"4","author":"Sultana","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B13","unstructured":"2024"},{"key":"B17","volume-title":"The first Union list of critical medicines","year":"2023"},{"key":"B23","volume-title":"The importance of pharmacovigilance","year":"2002"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med."},{"key":"B48","unstructured":"Guidelines for ATC classification and DDD assignment 2019. Oslo, Norway, 20182024"},{"key":"B49","unstructured":"Regulation and prequalification: pharmacovigilance. What is pharmacovigilance?2024"},{"key":"B50","volume-title":"International drug monitoring. The role of the national centres. Report of a WHO meeting","year":"1972"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1427772\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T23:26:11Z","timestamp":1733354771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1427772\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":50,"alternative-id":["10.3389\/fphar.2024.1427772"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1427772","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"article-number":"1427772"}}